Myelodysplastic Syndrome Treatment Options For Older Adults

MDS is a group of blood disorders in which the bone marrow does not produce enough healthy blood cells. It most commonly affects people over the age of 65, making age-related health factors a central part of how care is planned. Because MDS varies widely in its behavior and severity, no single treatment approach fits every patient. Instead, decisions are shaped by how the disease is classified, the patient’s overall health, and their personal goals for care.

How MDS Subtype and Risk Affect Treatment

One of the first steps after diagnosis is determining a patient’s risk category. Tools like the Revised International Prognostic Scoring System, or IPSS-R, help hematologists classify MDS as lower-risk or higher-risk based on factors such as bone marrow blast percentage, chromosome changes, and blood cell counts. This classification has a direct impact on which treatments are considered appropriate. Lower-risk MDS tends to progress more slowly and may not require aggressive intervention right away. Higher-risk MDS carries a greater chance of progressing to acute myeloid leukemia and often calls for more active treatment strategies.

Low-Risk and High-Risk MDS Care Options

For patients with lower-risk MDS, the primary focus is often on managing symptoms and maintaining quality of life. Erythropoiesis-stimulating agents, or ESAs, may be used to reduce anemia-related fatigue. Some patients with a specific chromosome deletion, known as del(5q), respond well to lenalidomide. In cases where ESAs are no longer effective, luspatercept has shown benefit for certain subtypes. For higher-risk MDS, hypomethylating agents such as azacitidine and decitabine are commonly used to slow disease progression. These are typically given in cycles and require regular monitoring. Stem cell transplant remains the only potentially curative option for eligible patients, though age and overall health must be carefully weighed before pursuing this path.

Supportive Care and Disease-Directed Treatment

Supportive care plays a meaningful role at every stage of MDS management. Red blood cell transfusions help manage severe anemia, while platelet transfusions may be used when bleeding risk is elevated. Iron chelation therapy is sometimes considered for patients who receive frequent transfusions and develop iron overload. These supportive measures do not alter the underlying disease but can significantly improve daily functioning and comfort. Disease-directed treatments, by contrast, aim to slow progression or modify how the bone marrow behaves. The balance between these two approaches depends on the individual’s risk profile, treatment tolerance, and personal priorities. For many older adults, maintaining independence and managing fatigue can weigh just as heavily as extending survival in treatment discussions.

Treatment Decisions for Older Adults With MDS

Age alone does not determine what treatment is appropriate, but it does introduce additional considerations. Older adults are more likely to have other health conditions, take multiple medications, and experience greater sensitivity to treatment side effects. Geriatric assessments, which evaluate physical function, cognitive health, and social support, are increasingly used alongside standard medical evaluations to guide treatment planning. Frailty assessments help identify patients who may benefit from less intensive approaches. Conversations about goals of care, including what matters most to the patient beyond survival, are considered an essential part of decision-making in this population.

Questions for a Hematology Consultation

Preparing for a visit with a hematologist or oncologist can help patients and caregivers make the most of limited appointment time. Some useful questions to consider include: What is my MDS risk category and what does that mean for my treatment options? Are there clinical trials that may be appropriate for me? How will treatment affect my daily routine and independence? What are the realistic goals of the recommended treatment, and how will we know if it is working? Asking about second opinions is also appropriate, particularly when treatment decisions involve significant trade-offs. Many academic medical centers have dedicated MDS programs where specialists focus specifically on these disorders.

MDS management in older adults requires a thoughtful, individualized approach that takes into account disease biology, health status, and personal values. As research continues to advance, new agents and combination strategies are expanding what is possible for patients across all risk categories. Staying informed, asking questions, and working closely with a knowledgeable care team remain the most reliable ways to navigate this complex condition.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.